The proportion of SCA3 (40.0%) patients in the CRC-SCA cohort is larger and the proportion of SCA2 (21.7%) is smaller than those in the European study population (SCA1: 117, 22.2%; SCA2: 163, 31.0%; SCA3: 139, 26.4%; SCA6: 107, 20.3%; p < 0.001 chi-square) [11]. This evidence concerns the gene ATXN3 and colorectal carcinoma.